Merck (MRK): People Won’t Even Buy Drugs
So much fore feeling better in a bad economy. Merck (MRK) offered lackluster guidance for next year and the stock is off before the open. According to Reuters, "Merck said it expected earnings, excluding…
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 347Can UnitedHealth Really Keep Its Targets? (UNH)
UnitedHealth Group Inc. (NYSE: UNH) has made some rather bold predictions for 2009. What is interesting here is that these projections are not showing continued growth nor showing total dominance. But the possible surprise…
J&J: Now Master Over Mentor (MNT, JNJ)
If you thought that high-premium buyouts or M&A was dead, that is not the case in at least some opportunities. Mentor Corp. (NYSE: MNT) has just secured a major premium buyout this Monday morning…
ZymoGentics Backers File To Sell Stock (ZGEN, NVO)
ZymoGenetics, Inc. (NASDAQ: ZGEN) has filed an SEC registration which would allow the company to sell up to $100 million of its common stock from time to time. What is important to note is…
Arena Raising R&D Funds (ARNA)
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) has filed to sell up to 25 million shares of common stock in a public secondary offering. Underwriters were not listed. Arena is a clinical-stage biotech company focused on…
Omrix Gets Acquired By J&J (OMRI, JNJ)
It looks as though not quite all the mergers are dead on the medical tech and biotechnology front. Johnson & Johnson (NYSE: JNJ) announced that it is acquiring Omrix Biopharmaceuticals, Inc. (NASDAQ: OMRI). The…
New Biotech Zombie: XTL Biopharma (XTLB)
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) is an Israeli biotech player that most traders have not heard of. By the looks of the trading today, it doesn’t look like shareholders will get to hear about…
The Worst May Not Be Over For MedCath (MDTH)
MedCath Corp. (NASDAQ: MDTH) took a particularly brutal beating at the end of last week after posting disappointing results. The stock fell nearly 50% on Friday to $7.55, a 52-week low against a period…
IPO Withdrawal: ChemoCentryx (GSK)
On Friday, ChemoCentryx Inc. filed to withdraw its pending registration for an IPO of up to $57.5 million. The market conditions of today are cited as the reasoning. The Mountain View, California-based company said…
Drug-Eluting Stent Data Shows More Promise (BSX, ANPI, JNJ, SRDX, MDT, ABT)
The Massachusetts Department of Public Health funded a study which is showing further evidence to support the use of drug eluting stents over bare metal stents in heart attack patients. This study measured stent…
Express Scripts’ PR Nightmare (ESRX)
Express Scripts Inc. (NASDAQ:ESRX) is about to have one massive PR nightmare in its hands. The pharmacy benefit management manager announced that it has received a letter from an unknown person or persons trying…
Almost Family Raising Cash (AFAM)
Almost Family Inc. (NASDAQ: AFAM) has filed a shelf registration that will allow the company to raise up to $150 million in securities sales. The company filed to sell any combination of Common Stock,…
Durect Files To Raise Cash (DRRX)
Durect Corporation (NASDAQ: DRRX) has just filed for a shelf registration to sell up to $75,000,000.00 worth of securities. This shelf will allow the company to sell any combination of common stock, preferred stock,…
Biogen Finds More PML In The Woodpile (BIIB)
Biogen Idec Inc. (NASDAQ: BIIB has notified regulatory agencies of a confirmed case of progressive multifocal leukoencephalopathy (PML) in a multiple sclerosis patient treated with TYSABRI .
Savient: Jim Cramer’s Old Favorite Biotech Implodes (SVNT)
Savient Pharmaceuticals Inc. (NASDAQ: SVNT) is feeling the wrath of the trading gods today. Shares are down some 74% at $2.95 in close to 10-times normal trading volume. The culprit for today’s biotech implosion…